Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
Open Access
- 1 January 2010
- journal article
- Published by Springer Science and Business Media LLC in Journal of Ovarian Research
- Vol. 3 (1), 22-8
- https://doi.org/10.1186/1757-2215-3-22
Abstract
We investigated the prognostic impact of changes in serum CA125 levels during the first 3 months of therapy in ovarian cancer.Keywords
This publication has 36 references indexed in Scilit:
- Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: A French multicentric studyGynecologic Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Serum CA-125 Level after 6 Cycles of Primary Adjuvant Chemotherapy Is a Useful Prognostic Factor for Complete Responders’ Survival in Patients with Advanced Epithelial Ovarian CancerOnkologie, 2008
- Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeAnnals Of Oncology, 2007
- Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancerGynecologic Oncology, 2006
- Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancerAPMIS, 2006
- Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinomaInternational Journal of Gynecologic Cancer, 2005
- CA-125 AUC as a new prognostic factor for patients with ovarian cancerGynecologic Oncology, 2005
- Carcinoma of the ovaryInternational Journal of Gynecology & Obstetrics, 2003
- CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1989